Vascepa (generic name: icosapent ethyl) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain cardiovascular conditions. The primary use of Vascepa is to lower the risk of cardiovascular events in adults with triglyceride levels of 150 mg/dL or higher, or who are on a statin medication and have elevated triglyceride levels (500 mg/dL or higher) [1].

Clinical trials have shown that Vascepa can help improve heart health by reducing the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death, in patients with established cardiovascular disease or diabetes and other risk factors [2]. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) was a large, randomized, double-blind, placebo-controlled trial that demonstrated a significant relative risk reduction of 25% in the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina requiring hospitalization [3].

It is important to note that Vascepa is not a substitute for a healthy lifestyle, including a balanced diet, regular exercise, and smoking cessation. Patients should consult their healthcare provider to determine if Vascepa is appropriate for their specific medical condition and to understand the potential benefits and risks associated with its use.

In summary, based on the available information, Vascepa can improve heart health by reducing the risk of cardiovascular events in certain patient populations. However, it should be used in conjunction with other lifestyle modifications and under the guidance of a healthcare professional.

Sources:
[1] Vascepa (icosapent ethyl) capsules, for oral use. Full Prescribing Information. Amarin Pharma Inc.; Thousand Oaks, CA: 2021. Available from: <https://www.vascepa.com/pdf/VASCEPA-PI.pdf>.
[2] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812797.
[3] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812797.
[4] DrugPatentWatch.com. Vascepa (icosapent ethyl) [online]. Available from: <https://www.drugpatentwatch.com/drugs/vascepa>.